Neogen (NEOG) is back in focus after expanding FIFRA Section 2(ee) recommendations for its Prozap insect control products in Texas and Florida, which gives livestock producers new options in New World Screwworm response efforts.
See our latest analysis for Neogen.
Despite the product update, Neogen’s recent share price momentum has softened, with the stock at US$8.83 and short term share price returns weaker, while the 1 year total shareholder return of 79.11% contrasts with deeper 3 and 5 year declines.
If this kind of regulatory news has you thinking about where else growth stories might emerge in markets tied to complex technology and infrastructure, it could be a good moment to scan 34 power grid technology and infrastructure stocks
Between the recent product update, a 79.11% 1-year total return, and deeper 3- and 5-year declines, is Neogen’s US$8.83 share price offering value, or is the market already pricing in any future growth?
Most Popular Narrative: 26.4% Undervalued
Neogen's most followed valuation story pins fair value at $12, which sits well above the last close at $8.83 and frames the recent share price pullback in a different light.
Ongoing global complexity and risks within the food supply chain, alongside heightened consumer expectations for food safety and transparency, will drive further adoption of Neogen's pathogen detection and digital solutions by food producers and regulators, expanding the company's addressable market and underpinning sustainable long-term revenue expansion.
Want to see how this food safety demand story turns into a $12 fair value for Neogen? The narrative leans on shifts in revenue mix, margin rebuild, and a richer future earnings multiple. The key details sit in the full model.
Result: Fair Value of $12 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still real pressure points for Neogen, including ongoing 3M Food Safety integration issues and softer Animal Safety demand tied to smaller cattle herds.
Find out about the key risks to this Neogen narrative.
Next Steps
If this combination of potential risks and rewards around Neogen leaves you uncertain, take a closer look now and weigh the 2 key rewards and 1 important warning sign
Looking for more investment ideas beyond Neogen?
If you stop with Neogen, you might miss opportunities that fit your goals even better, so make time to scan a few focused stock ideas.
- Target resilient income potential by reviewing companies in the 7 dividend fortresses that could help anchor your portfolio with cash returns.
- Hunt for mispriced opportunities by checking the 44 high quality undervalued stocks and see which stocks the data suggests may not match their fundamentals.
- Prioritise capital protection by scanning the 67 resilient stocks with low risk scores that aim to balance return potential with more controlled downside.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com